Trials / Terminated
TerminatedNCT04995783
Predicting Medication Response for Autoimmune Disease
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 200 (actual)
- Sponsor
- Coral Genomics, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Coral is conducting a large study comparing and predicting the relative effectiveness of different medications for autoimmune patients. Patients with Inflammatory Bowel Disease (IBD) who have been diagnosed with either Ulcerative Colitis or Crohn's Disease and are undergoing treatment are eligible to participate. Patients with Rheumatoid Arthritis (RA) and Psoriasis (Ps) will also be enrolled. A novel clinical test will be performed to predict the responsiveness of a particular patient to different immune modulating therapies used in these conditions.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | Coral FRS test | A novel clinical test to predict autoimmune medication response |
Timeline
- Start date
- 2020-09-01
- Primary completion
- 2022-08-01
- Completion
- 2022-08-01
- First posted
- 2021-08-09
- Last updated
- 2023-05-19
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT04995783. Inclusion in this directory is not an endorsement.